Jump to content

Search the Community

Showing results for tags 'Xofigo'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 7 results

  1. Jim Marshall (not a doctor) said ... Xofigo (Radium-223) has been recommended to go on the PBS. The conditions just published include: Previous Docetaxel, or unsuitability for Docetaxel; No previous enzalutamide (Xtandi) (or intolerance); No previous abiraterone (Zytiga) (or intolerance); So if a man has 2 or more bone metastases (mets) on the PBS his doctor will have to choose only one of: Xtandi (enzalutamide); Zytiga (abiraterone); Xofigo (Radium-233). If a man does not qualify for PBS Xofigo, doses cost about $7,000, with up to 6 dos
  2. During the phone-in meeting we held this morning (23 March 2018), there was discussion about Xofigo (Radium-223). The question arose of whether Xofigo gave both pain relief and longer survival. During that discussion, I mentioned that I had discussed Xofigo with American Medical Oncologist Alicia Morgans, and that this was on video. This is the video: A report on the ALSYMPCA trial of Xofigo (Radium-223) (previously called Alpharadin) can be found here. http://www.nejm.org/doi/full/10.1056/NEJMoa1213755 You can find all our videos on our YouTube
  3. Considerations relating to Radium-223 Therapy. I found this to be worthwhile for anyone with advanced metastatic disease predominately in the bones that may wish to discuss this treatment with their oncologist. Please note: The possible combination treatment with Abiraterone has been discontinued as it is now considered to be dangerous (see post on this site). However the rest of the presentation is informative and up to date. For a simpler more understandable version of Radium-223 Therapy check out our own JimJImJimJIm version on this site.Just go to the top bar and click o
  4. There are two committees that recommend public expenditure on medical treatments in Australia - the Medical Services Advisory Committee (MSAC) and the Pharmaceutical Benefits Advisory Committee (PBAC). The MSAC approved the use of Xofigo for prostate cancer patients in 2014. The PBAC announced approval of Xofigo for prostate cancer patients today (15 December 2017). The delays were due in part to this being the first treatment that needs to be paid for by both Medicare and the PBS. New rules had to be made. Ministerial approval can be expected in
  5. Radium-223 Radiographic Response: From the Desk of the Associate Editor URO Today Commentary by Andrew Armstrong, MD,ScM, FACP, USA This is a very brief summary of the take away from this study - Follow the link at the bottom of the article for complete details Radium-223 is best used early, before extensive soft tissue metastases occurs, and before the risk of spinal cord compression increases. (Note: Soft tissue disease is not being treated whilst Radium-223 therapy is being administered, it is not effective against soft tissue tumors.) For this reason when being treated with
  6. A member recently asked about the availability of Xofigo (Radium-223) in the UK: Xofigo in UK England Post-chemo on NHS Pre-chemo on Cancer Drugs Fund Scotland Pre-chemo on Scottish Medicines Consortium Post-chemo on Scottish Medicines Consortium Northern Ireland and Wales Pre-chemo not covered Post-chemo on NHS
  7. As you probably know, we have been campaigning to have the advanced prostate cancer treatment Xofigo (Radium-223) made available under Medicare for Australian men. As part of this, this week our Convenor, Jim Marshall (JimJimJimJim), will speak on this at events in Biloela and Nowra. Hosts in Biloela will be Ken O'Dowd MP, Member for Flynn, Qld and Biloela Mens Shed. Hosts in Nowra will be Ann Sudmalis MP, Member for Gilmore, NSW and the Bomaderry Advanced Prostate Men’s Group. Prostate Cancer Foundation of Australia (PCFA) CEO, Anthony Lowe, will also spea
×
×
  • Create New...